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Combined cell-gene therapy for lung cancer: rationale, challenges and 
prospects 
 
Abstract 
Lung cancer causes more deaths worldwide than any other cancer with most patients 
presenting with incurable metastatic disease. Mesenchymal stem cell tumour tropism 
presents us with an interesting mechanism of delivering potent therapies locally to 
cancers. Genetic modification of MSCs enables continued delivery of selective anti-
cancer treatments such as TRAIL. While this is an attractive therapeutic option, 
translating such a therapy into patients presents challenges both in manufacture and 
delineation of dose and dosing strategy. However, successful delivery of a combined 
cell-gene therapy in lung cancer may offer promise to thousands of individuals largely 
resigned to poorly effective palliative treatments. 
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1. Introduction 
Lung cancer is the leading cause of cancer-related deaths worldwide, with a 5-year survival of 
approximately 6% [1]. Around 80% of these are of non-small cell (NSCLC) histological type for which 
surgical resection or radical chemo-radiotherapy offers the best prospect of cure. The vast majority 
of cases however are diagnosed at an advanced stage, and therapy options are limited. Although, 
cisplatin-based chemotherapy trials in this group show a clear survival benefit over supportive care 
alone, the actual increase in median survival is small (4 vs 5.5 months) [2]. 
The landscape of treating stage IV disease changed around a decade ago with the discovery of the 
epidermal growth factor receptor (EGFR) mutations [3]. These were found in lung adenocarcinoma 
and were associated with a favorable response to EGFR tyrosine kinase inhibitors (TKIs). Whilst new 
targeted therapies have been introduced in routine clinical practice, they are only suitable for a low 
percentage of patients and outside of this outlook has changed little [3]. A better understanding of 
genetic changes in NSCLC have pushed the development of novel treatments for oncogenic drivers 
or actionable mutations as identified by preclinical evidence. However, only a small number of 
patients will benefit.  
Novel therapies are needed and we have developed a cell and gene therapy for the treatment of 
metastatic lung cancer. In this article we discuss some hurdles we face as we take our product into 
man in our recently funded phase I/II randomised trial, TACTICAL (Targeted stem cells expressing 
TRAIL as a therapy for lung cancer). 
 
2. Choosing an anti-cancer therapy 
The majority of patients with stage IV lung cancer will receive a platinum-based chemotherapy, with 
or without radiotherapy for palliative intent [3]. Chemotherapy is a non-targeted treatment that 
exhibits significant side-effects and toxicity whilst causing damage to healthy organs. The 
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characteristics of an ideal anticancer treatment should exhibit minimal systemic toxicity, and 
accurately target and kill only transformed cells, in both primary and metastatic sites. 
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) is a protein that causes cellular 
apoptosis in a pathway independent of p53 [4]. It is particularly attractive as a cancer therapy since 
it is able to selectively trigger apoptosis in transformed cells, leaving healthy cells unharmed. TRAIL 
works through the extrinsic apoptosis pathway (see figure 1), however some cross-talk does occur 
with the intrinsic system that responds to cellular stress, p53 activation and DNA damage [5]. 
Despite the promising results of recombinant TRAIL in vitro, failure in human trials when delivered 
intravenously have been attributed to its half-life of around 30 minutes. Investigators have since 
altered TRAIL to improve its therapeutic performance through ‘tagging’ with another protein to 
increase its size, or using a PEGylated form with protracted half-life and efficacy [5]. Monoclonal 
antibodies (MAbs) to TRAIL receptors have also been investigated, however, the presence of TRAIL 
decoy receptors and recruitment of immune have again led to disappointing results. Both 
recombinant TRAIL and monoclonal antibodies do not cross the blood-brain barrier, further limiting 
their use in the presence of lung cancer metastases. Therefore, ideally one would deliver TRAIL using 
a vehicle that homes to and resides at the site of the tumour, delivering a consistent dose of 
therapy. We and others have successfully used human bone marrow derived adult mesenchymal 
stem cells to deliver TRAIL as an anti-cancer therapy [6]. 
[Figure 1 near here] 
 
3. Mesenchymal stem cells: a vehicle to deliver anticancer therapies 
Stem cells are undifferentiated and have capacity for unlimited self-renewal, and multi- or 
pluripotent differentiation. Mesenchymal stromal stem cells (MSCs) are one of the best 
characterized adult stem cells and have emerged as attractive candidates for cell therapies. They are 
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present in virtually all tissues and can be derived from umbilical cord blood, adipose tissue, or most 
commonly, bone marrow [7]. MSCs have a direct immunosuppressive effect, which has been 
exploited in clinical studies over the last decade to treat graft versus host disease and other 
immunologically mediated conditions including acute and chronic pulmonary disease [4]. These 
studies have demonstrated that MSCs are safe, and low immunogenicity has obviated the need for 
human leukocyte antigen (HLA) matching of allogeneic cells [4]. 
MSCs have multiple characteristics that make them attractive as a cell therapy for cancer (see table 
1). The key feature being their ability to home to and engraft into tumours. Hence, they have 
potential to be used as a ‘Trojan Horse’ to deliver anti-cancer therapies. MSCs express chemokine 
receptors and cell adhesion molecules that aid in migration and homing to target tissues. Similar to 
leucocytes, MSCs may undergo both passive and active homing and chemotaxis is thought to be 
largely dependent on CXCR4, which binds to CXCL12, which is known to be overexpressed at tumour 
sites. In lung cancer we have demonstrated overexpression of macrophage inhibitory factor (MIF), 
which also binds CXCR4 maybe a key modulator of MSC tumour tropism [8]. 
MSCs have been modified and used as therapeutic vectors in several diseases [9]. In cancer, they 
have been successfully transduced with interferon-γ, interferon- β, thymidine kinase, or CX3CL1 
expressing vectors [4] resulting in effective inhibition of tumor growth in preclinical studies. One of 
the first trials in man will use MSCs genetically modified with herpes simplex virus thymidine kinase 
(HSV-tk) that activates pro-drug Ganciclovir [10]. This is a single-arm phase I/II study that will assess 
safety and efficacy of this treatment for advanced gastrointestinal cancers.  
Our group has produced and used MSCs that have been stably transfected with vectors containing a 
gene construct of TRAIL [6]. We have shown that this genetically modified cell therapy leads to 
either complete elimination or reduction of tumour growth when delivered intravenously in models 
of lung metastasis and mesothelioma. Despite the pre-clinical promise of gene and cell therapy 
there are a number of challenges to overcome before a product is ready for clinical use, from gene 
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transfer, to culture expansion of a clinical grade product and tracking the cells once delivered. 
[Table 1 near here] 
 
4. Combined cell & gene therapy for lung cancer: from bench to bedside 
4.1 Choice of viral vector and gene transfer 
Viral vectors gain entry, survive and transfer their genetic material into the host genome. The 
lentivirus is able to deliver large amounts of genetic information and infect both dividing and 
quiescent cells. They induce stable, long-term gene expression in the host, whilst avoiding insertion 
into oncogene promoters. The primary concern with viral vectors is the potential to create a 
replication-competent virus. Third-generation viruses for clinical use remove the virulent 
components and bundle it with a 4-plasmid system that contains information on the viral envelope, 
packaging, and the gene of interest. The packaging sequence is removed from all components other 
than the vector so they produce progeny only during virus manufacture. 
4.2 Mesenchymal stem cells: manufacture & release criteria 
MSCs constitute 0.002% of the bone marrow total stromal cell population [11]. Their classification is 
specified in the position paper by Dominici et al for the International Society for Cellular Therapy 
(ISCT) [12]. Although, MSCs are readily expandable up to 50 population doublings in 10 weeks, it has 
been suggested that in the clinic population doubling is kept below 20 for safety and efficacy [13]. 
One challenge therefore faced is developing a stem cell therapeutic product of scale to cope with 
clinical demand. A single donor bone-marrow derived MSCs expanded for 20 population doublings in 
the laboratory will generate approximately 1x108–1x109 cells. Since, most clinical trials using stem 
cells deliver MSCs doses of up to 5x106 /kg, each patient can require as many as 350 million cells per 
dose. Taking into account the number of patients in a trial, an excess of 100 billion cells will be 
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needed. In order to cope with manufacturing demands of this scale it is understandable that 
commercial suppliers look to the establishment of allogeneic pooled donor, cryopreserved cell banks 
that can simply be thawed when required. 
Since massive expansion of MSCs is required for cell therapy trials, conventional culture methods are 
not practical and closed-system bioreactors to culture cells on a large-scale are available. However, 
reducing biological divergence is key, with close regulation of cell density, population doubling 
times, frequency of media changes, and harvesting of adherent cells before down-stream processing 
and storage. Cryopreservation will be crucial to the storage of MSCs to deliver cell therapy for lung 
cancer on a large-scale. Whilst freeze-thawing leaves homing and adhesion molecules largely 
unharmed, we have shown there can be significant cell loss (around 20%) and disruption of MSC 
immune-modulatory properties (article in press). Therefore, protocols including that of storage time, 
freezing media composition, use of cryo-protectants and which cooling devices are used, all need to 
be optimized. 
Translating the product to the bedside requires strict compliance with regulations set out by the 
European Medicine Agency (EMA). This requires development of release criteria for a product 
before it is taken to the bedside. With there being a clear consensus on cell surface markers to 
identify MSCs and regulation of GMP facilities; the tripartite component of these criteria – 
identification, viability and sterility of MSCs pose little controversy [14]. However, some of the other 
challenges are summarized in table 2. The efficacy of MSCs should also be measured, using assays 
predictive of potency for its intended clinical application. The ISCT recently published their 
perspective on immune functional assays for MSCs as potency criteria [14]. Whilst there is limitation 
in defining the attributes of MSCs used in immune disorders, cells with a transferred gene often 
have a clearer read-out of potency.  
 7 
4.3 Tracking MSCs in man 
Optimal strategies for identifying the fate of MSCs following systemic infusion remain unclear. 
Although use of optical imaging to measure fluorescent and bioluminescent reporters has been 
successful in small animals, there is limitation with its depth of penetration when it comes to 
humans [15]. Magnetic resonance imaging used to detect stem cells loaded with super-
paramagnetic compounds are under investigation. However, positron emission tomography (PET) is 
likely to be at the forefront of cell imaging with development of new contrast agents. Investigators 
have combined HSV-tk with radioisotopes to image at high-resolution [15]. However, direct labelling 
of stem cells using novel radioisotopes may prove useful in tracking the fate of MSCs over longer 
periods of time, determining dosing schedules and in identifying any ‘off-target’ affects. 
[Table 2 near here] 
 
5. Expert Opinion 
Individuals with lung cancer most commonly present with advanced disease with little therapeutic 
option. Successful preclinical studies using genetically modified stem cells to treat cancer have paved 
the way for novel treatment in man. TRAIL selectively causes death in transformed cells and the use 
of MSCs overcomes previous problems of recombinant TRAIL half life by delivering the treatment 
direct to tumour sites. We have shown the delivery of ‘full-length’ TRAIL using MSCs rather than 
soluble TRAIL is superior and may overcome some cancer cell resistance seen with the recombinant 
form. Further improvements in efficacy are seen when combined with chemotherapy. This may be 
as a result of TRAIL induced interaction with the intrinsic death pathway or downregulation of 
inhibitors of apoptosis. Either way TRAIL appears potently synergistic with traditional lung cancer 
therapies.  
Translating this novel treatment into a full scale GMP approved processes for use in man is a 
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Herculean challenge. MSC culture and modification need careful attention and upscaling this process 
to safely deliver sufficient treatment doses whilst ensuring cell characteristics have been preserved 
is paramount. We are over coming the novel problems of large scale cell transduction as well as 
expansion of a cell and gene therapy product. This knowledge will hopefully be useful for the rapidly 
expanding field of cell and gene therapies. Regardless of the challenges faced, modifying MSCs to 
deliver TRAIL may offer tremendous promise to thousands who have little treatment option. 
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Tables & Figures 
Figure 1: TRAIL signaling activates apoptotic pathways. TRAIL acts on death receptors on the cell 
surface to activate the extrinsic pathway, while cellular stress and DNA damage causes apoptosis 
through the intrinsic pathway. 
FADD = FAS-activated death domain; BID = BH3 interacting-domain death agonist; BAK = Bcl-2 homologous 
antagonist; Cyt-C = cytochrome c; Apaf-1 = apoptotic protease-activating factor 1 
 
Table 1: Mesenchymal stem cell properties that make them ideal candidates for a cell therapy for 
cancer. 
Adapted from reviews on use of MSCs as engineered cell-therapies[4,15]. 
BM=bone marrow, PD=population doubling, MSC=mesenchymal stem cell, GvHD=graft-versus host disease, 
HSV-tk=herpes simplex virus–thymidine kinase, TRAIL= Tumour necrosis factor related apoptosis inducing 
ligand. 
 
Table 2: Cell therapy for lung cancer: addressing the challenges of clinical manufacture 
Adapted from table in ISCT perspective of immune functional assays for developing MSC-like products[14] and 
applied to delivery of our cell and gene therapy, MSC-TRAIL. 
ISCT=International Society for Cellular Therapy, MSC=Mesenchymal stem cell, TRAIL= Tumour necrosis factor 
related apoptosis inducing ligand 
